Royalty Report: Drugs, Therapeutic, Disease – Collection: 226889


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 226889

License Grant
The Licensor granted the Japanese Licensee an exclusive license for the development and commercialization of vadadustat.  Vadadustat, is a HIF-PH inhibitor, in Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD). Anemia is common in patients with CKD, and its prevalence increases as CKD progresses. Anemia is a condition characterized by abnormally low levels of hemoglobin.
License Property
The Licensor is a biopharmaceutical company focused on developing and commercializing novel therapeutics for patients based on hypoxia-inducible factor, or HIF. in patients with renal disease.
Field of Use
The Japanese Licensee will be responsible for certain development activities and commercializing vadadustat in the International Territory.

IPSCIO Record ID: 213595

License Grant
The Parties entered into a collaboration agreement providing Licensee with exclusive development and commercialization rights to vadadustat, the Company’s product candidate for the treatment of anemia related to chronic kidney disease, in Japan and certain other Asian countries, collectively, the Territory.  In addition, the Company will supply vadadustat for both clinical and commercial use in the Territory.
License Property
Vadadustat is the product candidate for the treatment of anemia related to chronic kidney disease.

The parties agreed to pursue a local development plan and, following consultation with the Japanese Pharmaceuticals and Medical Devices Agency, or the PMDA, Licensee initiated a local Phase 3 development for vadadustat in Japan, the Local Scenario.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 1152

License Grant
The Licensor and the Licensee have entered into agreements to develop and commercialize ferumoxytol as a therapeutic agent in China for an initial indication in the treatment of iron deficiency anemia in patients with chronic kidney disease, or CKD, and an option to expand into additional therapeutic indications.

The Licensee has agreed to purchase from us, and we have agreed to supply to the Licensee, ferumoxytol at a predetermined supply price for clinical and commercial use in connection with Licensee's development and commercialization obligations described above for so long as the License Agreement is in effect.

Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.